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The Association between the Measles, Mumps, and Rubella Vaccine and the 
Development of Autism: A Meta-Analysis  
 
Rashad Carlton 
 
ABSTRACT  
 
 Autism is a childhood developmental disorder characterized by impaired social 
interaction, difficulty with verbal and nonverbal communication and limited activities.  
The root cause of autism is unknown.  However it has been postulated that administration 
of the measles, mumps, and rubella (MMR) vaccine may be causally related to the 
development of autism.  MMR vaccination is a requirement for entry into schools, so any 
increase in adverse events associated with the vaccine carries widespread public health 
importance.   
The primary objective of this study was to conduct a meta-analysis of the 
association between the MMR vaccination and the development of autism.  The meta-
analysis was limited to studies with an experimental design, unvaccinated control group, 
and odds ratio or relative risk as the effect measure.  Both the fixed effects and random 
effects models were applied.   
 A total of 29 studies were identified for possible inclusion in the meta-analysis.  
After applying the inclusion/exclusion criteria seven studies were included in the meta-
analysis.  The pooled treatment effect was weighted based on the width of the 95% 
confidence interval for each of the individual studies.  The pooled effect measure for the 
seven studies was 1.052 (95% CI: 0.973, 1.138) (P=0.202).    
 v
 An association between the MMR vaccine and the development of autism was not 
found in this analysis.  Public health initiatives should continue to support mandatory 
vaccination with MMR for entry into school and steps should be taken to eliminate any 
barriers to vaccination.    Further epidemiological studies are needed to assess the root 
cause of autism.  
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Introduction 
 
Autism  
 Autism is a developmental disorder characterized by impaired social interaction, 
difficulty with verbal and nonverbal communication, and limited activities and interests 
(NINDS 2006).  Autism was first characterized in 1943 by Dr. Leo Kanner of Johns 
Hopkins Hospital, who termed the disease early infantile autism after studying a group of 
11 children (Strock 2007).  The Diagnostic and Statistical Manual of Mental Disorders 
(DSM –IV) classifies autism as one disease in a class of developmental disorders referred 
to as autism spectrum disorders (ASDs) or pervasive developmental disorders (PDDs) 
(Strock 2007, NINDS 2006).  Asperger syndrome, Rett syndrome, childhood 
disintegrative disorder, and pervasive developmental disorder not otherwise specified 
along with autism make up the ASDs.  Autism is the most common of the ASDs with an 
estimated three to six children out of 1,000 developing the disorder (NINDS 2006).   
 The most common sign of autism is impaired social interaction.  Autistic children 
usually do not know how to play interactively with other children (NINDS 2006).  
Autistic children commonly have difficulty learning and understanding the normal give-
and-take of social interaction.  Autistic children are typically slow to learn to interpret 
what others are thinking or feeling.  At times they may appear to be indifferent to others.  
This lack of social interaction results in the perception that they prefer to be alone (Strock 
2007).   
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Other common signs include problems with verbal and nonverbal communication, 
repetitive behavior, and obsessive interests (NINDS 2006).  In some cases autistic 
children remain mute their entire life.  Some autistic children develop verbal skills at a 
much later age than their peers.  Others will develop skills at a normal age but have 
difficulty communicating with others (Strock 2007).  Additionally, autistic children often 
engage in repetitive behavior such as rocking or twirling (NINDS 2006).  In most cases 
autistic children need and seek consistency in their environment.   The smallest changes 
in daily routines can be very disturbing for autistic children.     
 In addition to the developmental challenges associated with autism, autistic 
children are at higher risk for several comorbid conditions including fragile X syndrome, 
tuberous sclerosis, epileptic seizures, Tourette syndrome, learning disabilities, and 
attention deficit disorder.  Fragile X syndrome is an inherited form of mental retardation 
named for the part of the X chromosome that has a defective piece that appears pinched 
and fragile when viewed under a microscope.  Tuberous sclerosis is a genetic disorder 
that causes benign tumors to grow in the brain and other vital organs (Strock 2007).  
Approximately 20 to 30% of autistic children will develop epileptic seizures by 
adulthood (NINDS 2006).  In most cases the seizures can be controlled with 
pharmacologic therapy.  Most autistic children will have some degree of learning 
disability, with the degree of disability varying by child.  Often times, some areas of 
ability are normal, while one or more areas will show developmental delay.   
 The diagnosis of autism is challenging as autism varies widely in symptoms.  
Symptoms can range from mild to severe.  Parents are often the first to notice any 
symptoms of autism in their child.  There are several screening tools that can assist in the 
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screening for autism such as the Checklist of Autism in Toddlers, the Screening Tool for 
Autism in Two-Year-Olds and the Social Communication Questionnaire (Strock 2007).  
In order to establish an accurate diagnosis of autism, a comprehensive evaluation is 
required (NINDS 2006).  The evaluation should be performed by a multidisciplinary 
team consisting of a psychologist, neurologist, psychiatrist and speech therapist (NINDS 
2006).  Evaluation tools such as the Autism Diagnosis Interview Revised and the Autism 
Diagnostic Observation Schedule help in evaluating a child for autism.  The Autism 
Diagnosis Interview Revised is a structured interview of 100 questions consisting of four 
major factors: communication, social interaction, repetitive behaviors, and age of onset.  
The Autism Diagnostic Observation Schedule is an observational measure used to detect 
behaviors that are absent, delayed, or abnormal in children (Strock 2007).   
The National Institute of Neurological Disorders and Stroke list the following 
core behaviors that doctors rely on for a diagnosis of autism:  
• Impaired ability to make friends with peers 
• Impaired ability to initiate or sustain a conversation with others 
• Absence or impairment of imaginative and social play 
• Stereotyped, repetitive, or unusual use of language 
• Restricted patterns of interest that are abnormal in intensity or focus 
• Preoccupation with certain objects or subjects 
• Inflexible adherence to specific routine or rituals  
The diagnosis of autism is often complicated by other autism spectrum disorders.  
Children with insufficient symptoms to meet the criteria for autism are often classified as 
having pervasive developmental disorder not otherwise specified.  Children with 
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Asperger syndrome present with autistic symptoms but have well developed language 
skills (NINDS 2006).  Tools such as the Autism Spectrum Screening Questionnaire, the 
Australian Scale for Asperger’s Syndrome, and the Childhood Asperger Syndrome Test 
can help to distinguish Asperger syndrome from autism (Strock 2007).   Children with 
childhood disintegrative disorder develop normally and then deteriorate between the 
ages of 3 to 10, showing significant autistic symptoms (NINDS 2006).  After a diagnosis 
of autism is made, the next step is to identify appropriate treatment for the autistic child.   
 Currently there is no cure for autism and there is no single best treatment regimen 
for all children.  Current therapy is designed to alleviate specific symptoms and improve 
functional ability.  Treatment falls into two broad categories: educational/behavioral 
interventions and pharmacologic therapy.  Educational interventions include skill-
oriented sessions to help children develop social and language skills along with family 
counseling for parents and siblings of autistic children.  Pharmacologic therapy includes 
antidepressants to treat depression, anxiety, or obsessive compulsive disorder or anti-
psychotics to treat severe behavioral symptoms (NINDS 2006).   
The selective serotonin reuptake inhibitors such as fluoxetine, sertaline, and 
fluvoxamine are commonly used off-label to treat depression, anxiety, and obsessive 
compulsive disorder in autistic children.  In 2004, the Food and Drug Administration 
issued a “black box warning” alerting the public of the increased risk of suicidal ideation 
or suicide attempts in children and adolescents taking antidepressants.  In October 2006, 
the Food and Drug Administration approved risperidone for the symptomatic treatment 
of irritability in autistic children, representing the first drug with an FDA approved 
indication to treat symptoms in autism (Strock 2007).    In cases where autistic children 
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experience seizures, anticonvulsants are indicated.  Commonly prescribed 
anticonvulsants include: carbamazepine, lamotrigine, topiramate, and valproic acid.  
Autistic children with attention deficit disorder or hyperactivity can be treated with 
stimulant drugs, such as methylphenidate (Strock 2007).   There are also several 
controversial therapies available, but few if any have been scientifically proven to be 
effective (NINDS 2006).   
 The root cause of autism is unknown to date, and as of yet a biological marker for 
autism has not been found.  Several causative factors have been offered including 
genetics, environmental factors, abnormal levels of serotonin or other neurotransmitters 
in the brain, and vaccine administration.  It is strongly suspected that genetics plays 
some role because families with one autistic child have an approximately 5 percent risk 
of autism in a second child, which is much higher than the risk in the general population 
(NINDS 2006).  MRI studies of the brain have shown that many areas of the brain are 
abnormal in autism including the cerebellum, cerebral cortex, limbic system, corpus 
callosum, basal ganglia, and brain stem.  Research is ongoing to study what role these 
areas of the brain have in the development of autism along with the possible role of 
neurotransmitters such as serotonin, dopamine, and epinephrine (Strock 2007).   
In the past few years there has been widespread public concern regarding a 
proposed theory that autism was linked to vaccine administration.  The proposed link 
between autism and vaccines was first reported by Wakefield and colleagues in a case 
series study of 12 children with chronic enterocolitis and regressive developmental 
disorder (Wakefield 1998).  In 8 of the 12 children, the onset of behavioral problems was 
retrospectively linked to the measles, mumps, rubella (MMR) vaccination by a parent or 
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physician.   The Wakefield study gave rise to the proposed association of the MMR 
vaccine and the development of autism and created a major debate on the safety of the 
MMR vaccination.  Since the publication of the Wakefield study, several other studies 
have been conducted assessing the association between MMR vaccination and the 
development of autism.  Due to a lack of randomized controlled trials and conflicting 
results, there has not been enough evidence to support or definitively refute the 
hypothesized association between MMR and autism.   
 
Measles, Mumps, Rubella  
Measles 
 Since the inception of vaccinations for measles, mumps, and rubella the number 
of cases of these diseases has decreased by 99%. The success of the vaccinations has led 
to an attempt to eliminate these diseases.  A goal of the 1993 Childhood Immunization 
Initiative was to eliminate indigenous transmission of measles and rubella in the United 
States by 1996 (CDC 1998).  While these goals have not yet been achieved it appears that 
vaccination makes these goals feasible in the near future.   
 The first of these three diseases- measles also referred to as rubeola- is a disease 
characterized by a total body skin rash.  Measles is a highly contagious disease with an 
incubation period of 10-12 days from exposure to prodrome and 14 days from exposure 
to rash.  In the United States 1-2 out of every 1,000 cases results in death.  Infants and 
young children are at higher risk of death from measles and its complications.  The most 
severe complications of measles infection are pneumonia and acute encephalitis.  The 
rate of death from measles in less developed countries can be as high as 25%.  In 1963 
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the first measles vaccine was licensed.  Prior to this time an average of 400,000 measles 
cases were reported each year in the United States.  Since the inception of the measles 
vaccine, the number of cases of measles has decreased by 99% (CDC 1998).  Measles 
experienced a resurgence in the United States from 1989 to 1991.  There were more than 
55,000 cases of measles and over 120 measles related deaths.    The resurgence was led to 
a large degree by a number of unvaccinated preschool aged children residing in urban 
areas.   
In 1989 the Advisory Committee on Immunization Practices (ACIP) and the 
American Academy of Pediatrics (AAP) recommended that all children receive two 
doses of a measles-containing vaccine.  The implementation of the vaccination policy led 
to a decrease in the number of measles cases from 2,237 cases in 1992 to only 312 cases 
in 1993.  The challenges to eliminating and sustaining the elimination of measles are: 1) 
continuing to vaccinate all children aged 12-15 months with a first dose of MMR, 2) 
ensuring that all children have received a second dose of MMR before entering school, 
and 3) working with other countries to achieve measles elimination goals (CDC 1998).    
Mumps 
Mumps is a disease characterized by bilateral or unilateral parotitis.  The average 
onset of mumps is 16-18 days after exposure with nonspecific symptoms such as fever, 
headache, malaise, myalgia, and anorexia preceding parotitis.  Approximately 15%-20% 
of all mumps cases are asymptomatic and up to 50% of cases are associated with 
nonspecific respiratory symptoms.  The most serious complications of mumps such as 
male sterility and aseptic meningitis are more likely to occur in adults than children 
(CDC 1998).   
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 The mumps vaccine was first licensed in the United States in 1967. Since the 
inception of the mumps vaccine, reported cases of mumps have decreased by 99% from 
185,691 cases in 1968 to only 906 cases in 1995.  State laws requiring that children be 
vaccinated before school entry have significantly contributed to the decrease in reported 
cases of mumps.  The current two dose schedule of MMR likely further decreases the 
mumps incidence by immunizing children with a second dose as not all children generate 
an immune response following the first dose (CDC 1998).   
Rubella 
 Rubella is a disease characterized by nonspecific signs and symptoms including a 
pruritic rash, arthralgia, and low-grade fever.  The average incubation period is 12 to 23 
days and between 25-50% of all cases are subclinical.  Congenital rubella syndrome 
carries the risk of severe consequences such as miscarriages, stillbirth, fetal anomalies, 
and therapeutic abortions.  Children born with congenital rubella syndrome often have 
several abnormalities including sensory deficits, ophthalmic deficits, mental retardation, 
microcephaly, pulmonary artery stenosis, and atrial or ventricular septal defects (CDC 
1998).   
During the last major outbreak of rubella in the United States from 1964-1965, 
there were an estimated 20,000 cases of congenital rubella syndrome from 1964-1965.  
This led to the first rubella vaccine being licensed in 1969 with a target of children in 
kindergarten and the early grades of elementary school.  Following the initial vaccination 
campaign, cases of congenital rubella decreased by 69% from 1970 to 1976.  However, 
rubella outbreaks continued to occur in older adolescents and young adults.  ACIP 
modified the recommendations for immunization to include the vaccination of post 
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pubertal girls and women in 1977.  Cases of congenital rubella syndrome and rubella 
have occurred at a relatively constant endemic level with an average of less than 200 
cases with an occasional outbreak in persons over the age of 20 years.  An accurate 
incidence rate for rubella is difficult to estimate because rubella surveillance in the 
United States relies on a passive system (CDC 1998).  
Vaccine Preparations  
 Measles, mumps and rubella (MMR) vaccines are available as a combination 
vaccine, as well as monovalent vaccine for each specific agent.  Vaccines are also 
available as a combination of measles-rubella and a combination of rubella-mumps.  
Excipients included in each dose of the combined or monovalent vaccines are 0.3 mg of 
human albumin, 25 µg of neomycin, 14.5 mg of sorbitol and 14.5 mg of hydrolyzed 
gelatin.  The measles and mumps components are live vaccines produced in chick 
embryo cell culture and the live rubella vaccine is grown in human diploid cell culture 
(CDC 1998).   
 The strain of measles used in the vaccine has changed several times since the 
vaccine was first licensed in 1963.  Originally, both a live and an attenuated strain of 
vaccine were available.  Currently, only the Enders-Edmonston strain of measles licensed 
in 1968 is available in the United States.  Upon vaccination the measles vaccine produces 
a mild, noncommunicable infection with antibodies developing in 95% of children 
vaccinated at 12 months and 98% of children vaccinated at age 15 months.  Serologic and 
epidemiologic evidence indicates that the vaccine produces lifelong immunity in most 
persons (CDC 1998) 
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 The strain of rubella used in vaccines is a live strain of RA 27/3 first licensed in 
1979.  Serologic immunity is achieved in 95% of people aged 12 months or older who 
receive at least one dose of rubella vaccine.  Greater than 90% of vaccinated individuals 
have protection against both clinical rubella and viremia for at least 15 years.  There have 
been several reports of viremic reinfection following exposure among vaccinated 
individuals with low levels of detectable antibodies.  Additionally, rare cases of 
congenital rubella syndrome have occurred in infants born to mothers with documented 
serologic evidence of rubella immunity before they became pregnant (CDC 1998).   
 The mumps vaccine contains the live Jeryl-Lynn strain of mumps.  Vaccination 
with mumps vaccine produces a subclinical infection with few side effects.  In controlled 
clinical trials, over 97% of those vaccinated develop measurable immunity following 
vaccination.  Studies in the field report that the efficacy of the vaccine ranges from 75% 
to 95%.  Serologic and epidemiologic evidence suggest continuing protection against 
infection although the duration of immunity is unknown (CDC 1998).   
Vaccine Administration  
The Advisory Committee on Immunization Practices (ACIP) recommends the 
combined MMR vaccine as the vaccine of choice to protect against all three diseases 
unless contraindicated.  Two doses should be administered separated by at least one 
month in all children on or after their first birthday and in high risk adolescents and 
adults.  The second dose of MMR should elicit a response in the few individuals who do 
not elicit an immunological response to at least one component following their first 
vaccination.  Administering the vaccines in combination produces a similar response to 
receiving single-antigen vaccinations with measles, mumps, and rubella vaccines at 
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different sites or different times.  ACIP supports the administration of the MMR vaccine 
at the same time as other vaccines such as diphtheria, tetanus toxoid and acellular 
pertussis (DTaP), Haemophilus influenzae type b (Hib), oral polio vaccine or inactivated 
polio vaccine according to the schedule to receive vaccines  (CDC 1998). (See Appendix 
A)  
ACIP recommends that all children receive their first dose of MMR vaccine at 
age 12-15 months.  In certain high risk areas it is recommended that children receive their 
first dose by 12 months.  High risk areas are defined as: 
• A county with a large inner city population, 
• A county where a recent measles outbreak has occurred among unvaccinated 
preschool-aged children, or 
• A county in which more than five case of measles has occurred among preschool-
aged children each of the last 5 years. 
ACIP recommends that the second dose of MMR vaccine be administered when children 
are aged 4-6 years.  ACIP, the American Academy of Pediatrics (AAP), and the 
American Academy of Family Physicians (AAFP) have jointly adopted the 
recommended timing of the second dose of MMR.  ACIP encourages all states to adopt 
the two dose MMR requirement for preschool-aged children so that all 50 states will 
have a universal policy requiring: 
• For preschool-aged children: documentation of at least one dose of MMR vaccine 
administered on or after the first birthday, and  
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• For children in kindergarten through grade 12: documentation of two doses of 
MMR vaccine separated by at least 28 days with the first dose administered no earlier 
than the first birthday (CDC 1998).   
ACIP recommends that all people born in 1957 or later who do not have a 
contraindication to the MMR vaccine should receive at least one dose.  People born 
before 1957 are considered to be immune to measles, mumps, and rubella.  People 
considered being at high risk such as international travelers, persons attending colleges, 
and persons who work at healthcare facilities should receive special consideration for 
vaccination.  Additionally, all women of childbearing age who do not have acceptable 
evidence of rubella immunity should be offered vaccinations whenever they contact the 
healthcare system (CDC 1998).  
MMR Adverse Events  
 The range of adverse effects following the administration of the MMR vaccine 
ranges from common adverse events such as local pain and edema to the rare case of 
anaphylaxis.  An expert committee at the Institute of Medicine determined that evidence 
supports a causal relationship between MMR vaccination and anaphylaxis, 
thrombocytopenia, febrile seizures, and acute arthritis (CDC 1998).  Other adverse events 
reported in the MMR package insert include: vasculitis, otitis media, conjunctivitis, optic 
neuritis, ocular palsies, Guillan-Barre syndrome and ataxia (M-M-R II 2007).   
 In response to the adverse events caused by all vaccines including the MMR 
vaccine, The National Vaccine Injury Compensation Program (VICP) was created by the 
National Childhood Vaccine Injury Act of 1986. VICP works to resolve vaccine injury 
claims by providing compensation for people found to be injured by certain vaccines.  
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The US Department of Health and Human Services, the US Department of Justice, and 
the US Court of Federal Claims all have a role in VICP.  Compensation for injured 
parties as a result of vaccine administration is determined by the US Court of Federal 
Claims (HRSA).  VICP covers the following vaccines: 
• Diptheria, tetanus, pertussis (DTaP) 
• Haemophilus influenzae type b 
• Hepatitis A and Hepatitis B 
• Human Papillmovirus  
• Influenza 
• Measles, mumps, rubella (MMR) 
• Meningococcal 
• Polio 
• Pneumococcal conjugate 
• Rotavirus 
• Varicella  
Any person who has received a vaccine covered by VICP that believes that they 
were injured as a result of that vaccine may file a claim.  To file a claim the effects of the 
injury must have: 1) lasted for more than 6 months after the vaccine was given; or 2) 
resulted in a hospital stay and surgery; or 3) resulted in death.  There is no limit on the 
amount of compensation an injured party may receive.  The amount compensated is 
determined as a reasonable amount for past and future medical and custodial care costs 
and related expenses, lost earnings, reasonable lawyer fees and up to $250,000 for actual 
and projected pain and suffering.  A claim must be filled within 3 years after the first 
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symptom of the vaccine related injury or within 2 years of death or 4 years after the first 
symptom of the vaccine related injury (HRSA 2008).   
Since the inception of VICP there have been 774 claims against the MMR 
vaccine.  A total of 271 cases resulted in compensation being paid to the claimant, 323 
claims were dismissed, and 180 claims are still pending.   Since 1989, there have been 
2,865 claims filed for non-autism related injuries and 5,263 claims for autism related 
injuries across all vaccinations.  Since 1990, only one autism case has been deemed 
compensable to date and 350 cases have been dismissed (HRSA 2008). The remaining 
autism-related cases are still awaiting a ruling.    The debate of whether autism is causally 
linked to vaccine administration and therefore should be compensated under VICP is still 
ongoing and has a potentially significant impact on public health.     
Table 1. National Vaccine Injury Compensation Program-Post 1988 Statistics Report of 
Petitions Filed  
 
Fiscal Year Non-Autism Autism Total 
FY 1989 1 0 1 
FY 1990 29 0 29 
FY 1991 118 0 118 
FY 1992 186 0 186 
FY 1993 137 0 137 
FY 1994 106 0 106 
FY 1995 179 0 179 
FY 1996 84 0 84 
FY 1997 103 0 103 
FY 1998 116 0 116 
FY 1999 405 1 406 
FY 2000 161 0 161 
FY 2001 196 18 214 
FY 2002 189 768 957 
FY 2003 152 2,437 2,589 
FY 2004 126 1,088 1,214 
FY 2005 146 587 733 
FY 2006 154 169 323 
FY 2007 238 168 406 
FY 2008 39 27 66 
Total  2,865 5,263 8,128 
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Table 2. National Vaccine Injury Compensation Program Post 1988 Statistics Report for 
Adjudications of Claims  
 
Fiscal Year 
Non-Autism Autism 
Total 
Compensable Dismissed Sub-Total Compensable Dismissed 
Sub-
Total
FY 1990 2 0 2 0 0 0 2
FY 1991 10 22 32 0 0 0 32
FY 1992 30 43 73 0 0 0 73
FY 1993 22 57 79 0 0 0 79
FY 1994 41 43 84 0 0 0 84
FY 1995 48 51 99 0 0 0 99
FY 1996  50 78 128 0 0 0 128
FY 1997  60 51 111 0 0 0 111
FY 1998  53 72 125 0 0 0 125
FY 1999  38 73 111 0 0 0 111
FY 2000  67 75 142 0 0 0 143
FY 2001 66 79 145 0 0 0 145
FY 2002 98 95 193 0 4 4 197
FY 2003 52 74 126 0 21 21 148
FY 2004 60 120 180 0 113 113 293
FY 2005 60 69 130 0 51 51 181
FY 2006 67 76 145 0 107 107 249
FY 2007 80 71 151 0 32 32 183
FY 2008 21 9 30 1 22 23 53
Totals  924 1,158 2,082 1 350 351 2,433
 
Thimerosal  
 A second hypothesis dealing with vaccine administration and the development of 
autism contends that thimerosal, a mercury containing preservative that has been used in 
some vaccines and other pharmaceutical products since the 1930s, is the agent causing 
autism.  Thimerosal was contained in over 30 childhood vaccines including Haemophilus 
influenzae type b, hepatitis B, and DTaP up until 1999. Thimerosal was never used as a 
preservative for the MMR vaccine because thimerosal would inactivate the live vaccine.  
The thimerosal hypothesis gained credibility after FDA researchers determined that the 
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childhood vaccination schedule might expose children to cumulative doses of ethyl-
mercury that exceed some federal safety guidelines (IRSC 2004).   In 2001, the Institute 
of Medicine concluded that the evidence was inadequate to accept or reject a causal 
relationship between exposure to thimerosal and the development of autism (IRSC 2004).  
As of March 2001, all formulations of vaccines for childhood immunizations are free of 
thimerosal (IRSC 2004).   
 
Healthy People 2010  
 Healthy People 2010 is a declaration of the national health objectives designed to 
identify the most significant preventable threats to health and to establish national goals 
to reduce these threats.  The two primary goals of Healthy People 2010 are to increase the 
quality and duration of healthy life and to eliminate health disparities.  There are 28 focus 
area chapters in Healthy People 2010 and each chapter contains a concise goal statement.   
The goal of Healthy People 2010 pertaining to immunizations and infectious disease is to 
prevent disease, disability, and death from infectious diseases, including vaccine 
preventable diseases (Healthy People 2010).   
Healthy People 2010 includes specific goals and objectives under each chapter 
outlining goals and methods for improving health.   The overall goal of Chapter 14: 
Immunization and Infectious Diseases, is to reduce or eliminate indigenous cases of 
vaccine-preventable diseases. Healthy People 2010 attempts to build upon the progress 
that was made toward meeting the Healthy People 2000 objectives.  As an example, the 
number of cases of measles decreased from 3,396 indigenous cases in 1988 to only 74 
 17
cases in 1998 (Healthy People 2010).  A primary objective under this goal is the 
elimination of all cases of measles, mumps, and rubella. 
The achievement of a high level of coverage for two doses of MMR vaccine 
makes the goal of eliminating measles, mumps, and rubella feasible.  In 1998 the baseline 
immunization rate for at least one dose of the MMR vaccine was 92%.  The Healthy 
People 2010 goal is to maintain at least 90% coverage for one dose of the MMR vaccine.  
It is believed that coverage of at least 90% is sufficient to prevent the circulation of 
viruses and bacteria-causing disease.  However, even with the achievement of 90% 
coverage levels it is imperative to monitor subgroups of the population that are under 
vaccinated.  These groups of under vaccinated individuals increase the possibility of a 
major outbreak of a vaccine preventable disease.  Eliminating potential health disparities 
is a necessary measure to achieving the goal of eliminating all cases of measles, mumps, 
and rubella (Healthy People 2010).  
Another objective of the chapter on immunization and infectious diseases from 
Healthy People 2010 that builds upon Healthy People 2000 is to maintain vaccination 
coverage levels for children in licensed day care facilities and children in kindergarten 
through the first grade.  The goal for the MMR vaccine is 95% for children in day cares 
and children in kindergarten to first grade.  As measured in Healthy People 2000, the 
individual coverage rates for three or more doses of polio, three or more doses of 
diphtheria/tetanus/acellular pertussis (DTaP), one or more doses of MMR and three or 
more doses of Haemophilus influenzae type b vaccines were each at or above 91 percent 
(Health People 2010).  Increasing the coverage rate to 95% for all children entering a 
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licensed day care facility or entering school represents a significant step to eliminating all 
cases of vaccine preventable diseases.   
 Healthy People 2010 also outlines strategies to achieve the outlined goals and 
objectives.  Major strategies to protect people from vaccine preventable diseases include: 
• Improving the quality and quantity of vaccination delivery services, 
• Minimizing financial burdens for needy persons, 
• Increasing community participation, education and partnership, 
• Improving monitoring of disease and vaccination coverage rates, and 
• Developing new or improved vaccines and improving vaccine use.  
Programs such as Vaccines for Children and SCHIP have made vaccinations available 
for children.  These programs along with the requirements of vaccinations for entry into 
day care and schools have increased the vaccination rate (Healthy People 2010).  
Improvements in the vaccination rate not only extend benefits to those that are 
vaccinated, benefits of vaccination are gained by society as a whole.  In cases where a 
few people cannot be vaccinated, if the vaccination level in the community is high these 
people are protected due to group or “herd” immunity, whereby the unvaccinated group 
has a decreased risk of contracting a disease because all those around them have been 
vaccinated.  Achievement of the Healthy People 2010 MMR vaccination goals will go a 
long way toward eradicating measles, mumps, and rubella.   
It is hypothesized that administration of the MMR vaccine is causally related to 
the development of autism.  The hypothesis was first proposed by Wakefield and 
associates (Wakefield1998) following a case study of 12 children with gastrointestinal 
disorders and developmental regression.  In 8 of the 12 children, the parents or the 
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physician retrospectively linked the onset of the behavioral problems with the 
administration of the MMR vaccine.  While the authors concluded that there was 
insufficient evidence in their study to support a causal relationship, the study generated a 
hypothesis warranting further research.   The purpose of this research is to evaluate if a 
causal relationship exists between childhood vaccination with MMR and the development 
of autism by applying the statistical methods of a meta-analysis of published primary 
literature.   
 
 20
 
 
 
Methods 
  
The primary objectives of this analysis are to:  
1. Assess the causal relationship between the MMR vaccine and the development of 
childhood autism, and  
2. Discuss the impact of the association of the MMR vaccine and the development 
of autism on the ACIP vaccination guidelines and the Healthy People 2010 goal 
for immunizations against preventable diseases. 
A quantitative meta-analysis was conducted to assess the causal relationship 
between the MMR vaccine and the development of autism.  A comprehensive literature 
search of PubMed and Medline assessing the relationship between the MMR vaccine and 
the development of autism during the years 1998 to 2007 was conducted.  Key search 
terms for the systematic literature review included: autism, autistic, MMR, measles, 
mumps, and rubella alone or in combination. The search was limited to articles published 
in the English language.  A total of 29 studies were identified.  
The following study inclusion criteria were employed on the 29 studies. 
1. Appropriate study design (e.g. prospective or retrospective case-control or cohort 
study 
2. Study must contain a control group 
3. Study endpoints must report or allow for the calculation of the effect measure and 
a standard error or confidence interval for the association of MMR vaccination 
and the development of autism (odds ratio or relative risk)  
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4. Experimental group must have received MMR vaccination  
5. Adequate sample size (n≥100)  
The following study exclusion criteria were employed:   
1. Study does not have an unvaccinated comparison group (e.g. case report/case 
series) 
2. Study endpoints do not allow for the calculation of an odds ratio or relative risk  
3. Study exposure does not include the MMR vaccination 
4. Study is not independent of another study included in the analysis (e.g. re-analysis 
of the same study population)  
After applying the inclusion/exclusion criteria seven studies remained for 
inclusion in the meta-analysis (see Appendix B).  Statistical analyses combining and 
interpreting the results of independent studies were conducted to integrate the results of 
several studies and arrive at a conclusion on the causal association of the MMR vaccine 
and autism. 
The patient population included children (<18 years) who have received the 
MMR vaccine under a normal vaccination schedule according to ACIP guidelines or 
appropriate guidelines for their country.   
Study Endpoints will include:  
• Effect measure  
o Odds ratio/relative risk for each individual study 
o Pooled effect for the association between MMR vaccination and the 
development of autism  
• Meta-regression  
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o Meta-regression to assess the impact of continuous predictors (e.g. age at 
vaccination, number of vaccinations)  
The odds ratio of the association between the MMR vaccine and the development 
of autism was measured for each individual study as the effect measure. The pooled 
effect measure was then calculated based on the weighted average of the effect measures 
seen in each study.  The weight for each study was determined based on the width of the 
95% confidence interval for the effect measure of each study.  The meta-analysis was 
conducted using both a fixed and a random effects model.   A sensitivity analysis was 
conducted to assess the impact of individual studies on the pooled effect measure.  
Publication bias was assessed using a funnel plot and the trim and fill technique.  Data 
analysis will be conducted using Comprehensive Meta Analysis (CMA) Version 2.0, a 
computer program for meta analysis developed by a team of experts from the US and 
U.K. and funded by the US National Institutes of Health. 
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Results 
 
Descriptive Statistics  
 
 Seven out of 29 studies met all inclusion/exclusion criteria. Fifteen studies were 
excluded due to the lack of an unvaccinated control group (Studies 1, 2, 3, 5, 6, 9, 12, 13, 
15, 16, 17, 21, 22, 27, and 28).  Three studies were excluded for the lack of MMR 
exposure in the study (Studies 7, 11, and 25).  Three studies were excluded because they 
did not allow for the calculation of an effect size (Studies 18, 19, and 29).  One study was 
excluded because it was a secondary analysis of a previous study that was included in the 
meta-analysis (Study 4).   
 The following seven studies were included in the meta-analysis: Madsen 2002, 
Honda 2005, Smeeth 2004, Taylor 1999, Uchiyama 2007, Goldman 2004 and Taylor 
2002.  
Table 3. Synopsis of Included Studies   
Study Design Country Years Dependent 
Variable  
Madsen 2002 Retrospective 
cohort study 
Denmark 1991-1998 Autism or ASD 
Honda 2005 Cohort study Japan 1988-1996 ASD  
Smeeth 2004  Case-control 
study 
United 
Kingdom 
1987-2001 Autism or ASD 
Taylor 1999 Epidemiological 
study 
United 
Kingdom 
1979-1992 Autism 
Uchiyama 2007 Epidemiological 
study 
Japan 1976-1999 ASD 
Goldman 2004 Retrospective 
cohort study 
Denmark 1980-1992 Autism 
Taylor 2002 Population 
study 
United 
Kingdom 
1979-1992 Autism 
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Madsen 2002 was a retrospective cohort study of all children born in Denmark 
including a total of 537,303 children.  Vaccination status was obtained from the National 
Board of Health and information on autism status was obtained from the Danish 
Psychiatric Central Register.  A total of 316 children were diagnosed with autism and 422 
with an autism spectrum disorder.  The relative risk for autistic disorder in the 
unvaccinated group compared to the vaccinated group was 0.919.  
 Honda 2005 was a cohort study of children up to age seven born between 1988 
and 1996 in Kohoku Ward of Japan.  All children born in 1993 or after did not receive a 
single vaccination of MMR.  The cumulative incidence of autism spectrum disorders 
increased significantly in the birth cohorts from 1988 through 1996 with the most notable 
increase beginning with the 1993 birth cohort.  The odds ratio for the association between 
MMR and autism was 1.921.  
 Smeeth 2004 was a matched case-control study using the U.K. General Practice 
Research Database.  Cases were people born in 1973 or later who were diagnosed with a 
pervasive developmental disorder, between 1987 and 2001.  Controls were matched on 
age, sex, and general practice.  A total of 1294 cases and 4469 controls were included in 
the study.  The odds ratio for the association of MMR and autism was 0.880.    
 Taylor 1999 was an epidemiological study of children from eight North Thames 
health districts in the U.K.  Information from clinical records of the children was linked 
to immunization data held on the child health computing system.  Any clustering of onset 
of autism in post vaccination periods were investigated using the case series method.  A 
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total of 498 cases of autism were identified.  The odds ratio for the association of MMR 
and the development of autism was 0.940.  
 Uchiyama 2007 was an epidemiological study of the association between MMR 
vaccination and the development of autism in Japan.  Since the MMR vaccine was only 
used in Japan between 1989 and 1993, this time period affords a natural experiment for 
MMR and autism.  The study included an analysis on 904 patients with autism spectrum 
disorder.  The analysis included cohorts from three periods: before, during, and after 
MMR usage.  There were no significant differences in the incidence of autism in the 
cohort that received MMR and those who had not with an odds ratio of 0.744.   
 Goldman 2004 investigated the prevalence of autism by age category from 1980 
to 2002 using a nationwide computerized registration system with the Danish Psychiatric 
Central Register.  The MMR vaccine was added to the immunization schedule of 
Denmark in 1987.  Linear regression analysis was used to investigate compare the 
periods preceding and following the introduction of the MMR vaccine.  Longitudinal 
trends in the prevalence data suggest a temporal association between the introduction of 
MMR vaccine and the rise in autism with an odds ratio of 4.700.   
 Taylor 2002 was a population study with case note review of five health districts 
in north east London.  The study population included 278 children with core autism and 
195 with atypical autism identified from computerized disability registers born between 
1979 and 1998.  The odds ratio for the association of MMR and the development of 
autism was 0.980.    
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Meta-Analysis Results  
 Two of the seven studies included in the meta-analysis suggested a causal 
association between MMR and autism and five studies did not suggest a causal 
association.  The combined effect measure using a fixed effects model was 1.052 (95% 
CI: 0.973, 1.138; p value= 0.202).  The weights assigned for the studies based on the size 
of the confidence intervals under a fixed model were: 6.99% for Madsen 2002, 5.22% for 
Honda 2005, 8.35% for Smeeth 2004,  3.04% for Taylor 1999, 1.13% for Uchiyama 
2007, 3.43% for Goldman 2004, and 71.84% for Taylor 2002.  When using a random 
effects model, the combined effect measure was 1.267 (95% CI: 0.879, 1.827; p 
value=0.204).  In the random effects model the studies weights were: 15.31% for Madsen 
2002, 14.81% for Honda 2005, 15.56% for Smeeth 2004, 13.55% for Taylor 1999, 
10.08% for Uchiyama 2007, 13.87% for Goldman 2004, and 16.82% for Taylor 2002.   
 
Figure 1. Meta-analysis results: Autism and MMR  
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Madsen 2002 0.919 0.684 1.234 -0.563 0.574
Honda 2005 1.921 1.365 2.704 3.743 0.000
Smeeth 2004 0.880 0.672 1.153 -0.928 0.354
Taylor 1999 0.940 0.601 1.471 -0.271 0.787
Uchiyama 2007 0.744 0.357 1.551 -0.789 0.430
Goldman 2004 4.700 3.084 7.163 7.199 0.000
Taylor 2002 0.980 0.894 1.075 -0.430 0.667
1.052 0.973 1.138 1.276 0.202
0.01 0.1 1 10 100
No Association Association
Meta Analysis
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Figure 2. Meta-analysis results: Funnel Plot  
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Sensitivity Analysis 
 The meta-analysis was conducted removing the outlier study, Goldman 2004, in 
the sensitivity analysis.  The combined effect measure for the 6 studies excluding 
Goldman 2004 was 0.998 (95% CI: 0.921, 1.080; p value=0.953) when using a fixed 
effects model.  When using a random effects model the combined effect measure was 
1.035 (95% CI: 0.835, 1.281; p value=0.755).  The funnel plot assessing publication bias 
revealed no publication bias as the studies were symmetrical.  Most studies assessing the 
association between MMR and the development of autism fall in the range of no 
association.  The Goldman 2004 and Honda 2005 studies fall outside of the funnel, 
indicating that they were outliers.   
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Discussion 
 
 The results of this meta-analysis did not find a causal association between MMR 
vaccination and the development of autism.  The combined fixed effect measure of 1.052 
includes a 95% CI from 0.973 to 1.138 that crosses one, thus making the results non-
significant.  The same scenario occurs when using a random effects model with an effect 
measure of 1.267 and a 95% CI from 0.879 to 1.827.  In both a fixed and random effects 
model the meta-analysis did not find a causal association between MMR vaccination and 
the development of autism. Due to the small number of studies included the study may 
not have had adequate power to detect a difference if one existed. 
 The two studies included in the meta-analysis that supported an association 
between MMR vaccination and the development of autism are potentially biased by time.  
Goldman 2004 examines the prevalence of autism by age category from 1980 to 2002 
using a computerized registration system in Denmark.  The study provided a comparison 
of prevalence rates pre and post licensure of the MMR vaccine.  Prevalence rates in the 
post licensure period may have been much higher than in the pre licensure period due to 
greater diagnostic awareness and an overall increasing prevalence of autism.    
Studies such as Dales 2001 and Kaye 2001 have found an increasing prevalence 
of autism over time.  Dales 2001 was a time trend analysis of the association of autism 
and MMR vaccination coverage in California.  Dales 2001 showed a sustained increase in 
autism cases from 44 cases per 100,000 births in 1980 to 208 cases per 100,000 live 
births in 1994 with minimal change in MMR vaccination rates.  The changes in the 
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prevalence rates seen in this study provide evidence that MMR vaccination was not the 
cause of the increased prevalence of autism.  Similarly, Kaye 2001 was a time trend 
analysis of autism prevalence in the UK from 1988 to 1999.  The incidence of autism 
increased sevenfold from 1988 to 1999 with the vaccination rate staying above 95% over 
the entire timeframe.  This suggests that some other factor was the root cause of the 
increasing prevalence of autism and not MMR vaccination.   
 The association found in Honda 2005 may have been influenced by the same time 
factor bias as Goldman 2004.  In Honda 2005, the cumulative incidence of autism 
spectrum disorders were examined from 1988 to 1996 in the Kohoku ward of Japan.  The 
population was divided into vaccinated and unvaccinated populations based on MMR 
vaccination being discontinued in 1993.  The association that was found may have been 
influenced by time with the two cohorts being determined by the time when MMR 
vaccination was available.   
 There are several possible explanations for the apparent increase in autism 
prevalence.  Changes in the prevalence of autism may be influenced by: substantial 
migration of affected children into or out of a community, change in age of onset or 
recognition, large changes in denominator population, increased ascertainment of 
children with diagnoses of autism, a change in diagnostic criteria to include individuals 
with milder symptoms, and a true increase in the incidence of the disease, which can be 
attributable to new environmental exposures (Halsey 2001).  Studies to determine the 
prevalence of autism are very susceptible to bias and therefore prevalence rates in the 
literature vary considerably.  The increased attention and better understanding of autism 
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has likely led to a greater diagnostic awareness accounting for a portion of the increased 
prevalence.   
 Vaccination rates and vaccine safety are major issues of concern for public health.  
An adequate vaccination history is routinely a requirement for school entry.  Reasonable 
concerns about the safety of childhood vaccines would require an examination of the 
vaccine schedule and the legality of requiring children to be vaccinated before entering 
school.  The evidence in this case did not find a causal association between MMR 
vaccination and the development of autism.  As such, public health initiatives should 
focus on achieving the Healthy People 2010 goals of eliminating vaccine preventable 
diseases.  Measles, mumps, and rubella pose significant risks to the health of 
unvaccinated children.  Media attention and parental concern about the safety of the 
MMR vaccine has led some parents to withhold the vaccination from their child.   
Disseminating evidence on the safety of the MMR vaccine should be a major public 
health initiative.  Educating parents on the safety of the vaccine and the potential dangers 
of measles, mumps, and rubella is the first step to increasing the vaccination rate and 
eventually eliminating these three diseases.   
 In order to adequately address the problem of autism more information is needed 
on the root cause of the disease.  Areas that require further study include factors 
associated with autism including genetics and environmental exposure in utero and 
during the first few months after birth, or temporally associated with the onset of 
symptoms (Halsey 2001).  One of the primary reasons that MMR vaccination was 
believed to be a cause of autism was the close temporal relationship between MMR 
vaccination and the onset of symptoms.  According to the Recommended Vaccination 
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Schedule (Table 1), the MMR vaccine is given at 12-15 months, which coincides with the 
typical onset of autism.  During the 12-15 months of age period, children are receiving 
several vaccines that may have some role in the development of autism.  Additionally, 
presentation with autism at this early age would suggest that there may be genetic or in 
utero factors that are causally associated with autism development.   Weiss and associates 
reported an association between microdeletion and microduplication on chromosome 
16p11.2 (Weiss 2008).  This novel microdeletion and microduplication carries a 
substantial susceptibility to autism, but it only accounts for approximately 1% of all 
autism cases.  The identification of this one genetic factor responsible for 1% of all 
autism cases may be just the beginning of uncovering the genetic link to autism.   
 Another area for future research is the incidence of regression in people with 
autism.  Wakefield and associates first hypothesized that the MMR vaccine was 
associated with a ‘regressive’ phenotype of autism (Wakefield 1998).  Further study on 
the nature and incidence of people with ‘regressive’ autism may show a certain group of 
individuals who are genetically predisposed or have some other factor that triggers 
regressive autism.  It may be possible that the MMR vaccine or some other 
environmental exposure around the time of MMR vaccination may trigger the onset of 
regressive autism.   
 There is the potential that a previously unrecognized infectious agent may affect 
persons with autism.  A close temporal relationship between MMR vaccination and onset 
of autism symptoms led to the proposed causal association.  In the 12-15 months of life 
before MMR vaccination, children are exposed to several potentially infectious agents.  
Like previous infectious diseases such as HIV, it may be years before a causative 
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pathogen is identified.  It is vital that continued scientific efforts be directed to the 
identification of the cause or causes of autism and ways to avoid this debilitating disease.   
 The strengths of this study include population-based data, inclusion of an 
unvaccinated control group, and large total sample size.   Limitations of the study include 
small number of studies included, retrospective data collection for some studies, 
differences in the dependent variable, differences in vaccination policies across countries, 
recording of data may have been incomplete or inaccurate, and the inability to control for 
potential confounders such as time, greater diagnostic awareness and age at vaccination.  
The quality of the meta-analysis is limited by the limitations of each individual study.   
 
Conclusion  
 This study does not support a causal association between the MMR vaccine and 
the development of autism.  Public health initiatives are needed to promote the safety of 
the MMR vaccine and to increase the vaccination rate.  Increasing the vaccination rate for 
MMR will generate progress toward eliminating measles, mumps, and rubella as 
childhood diseases.  Further epidemiological research on the root cause of autism should 
focus on a genetic link or environmental factors in the early stages of life. 
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Appendix A Recommended Immunization Schedule 
 
Table 4. Recommended Immunization Schedule for Ages 0-6  
 
Vaccine    Birth 1 
month 
2 
months 
4 
months 
6 months 12 
months 
15 
months 
18 
months 
19-23 
months 
2-3 
years 
4-6 
years 
Hepatitis B Hep B Hep B  Hep B    
Rotavirus   Rota Rota Rota       
Diphtheria, Tetanus, 
Pertussis  
  DTaP DTaP DTaP  DTaP    
Haemophilus 
influenzae type b 
  Hib Hib Hib Hib     
Pnuemococcal   PCV PCV PCV PCV   PPV 
Inactivated 
Poliovirus 
  IPV IPV IPV    
Influenza     Yearly 
Measles, Mumps, 
Rubella 
     MMR    MMR 
Varicella      Varicella     
Hepatitis A      HepA (2 doses) Hep A Series 
Meningococcal          MCV4 
 
Key:           = Range of recommend ages              = Certain high-risk groups  
Adapted from: Recommended Immunization Schedule for Persons Aged 0-6 Years- United States 2008. Approved by the Advisory Committee on Immunization 
Practices, the American Academy of Pediatrics and the American Academy of Family Physicians.  Available at: www.cdc.gov/vaccines.recs/shedules  
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Appendix B Research Review 
Table 5. Research Review  
 
Citation Design Information Outcome Measures Results Key Assumptions/ 
Limitations  
Inclusion/ 
Exclusion 
1. Dales L, 
Hammer SJ, 
Smith NJ. Time 
trends in autism 
and MMR 
immunization 
coverage in 
California. 
JAMA 
2001;285(9): 
1183- 1185.  
Objective: To 
determine if a 
correlation exists in 
secular trends of 
MMR immunization 
coverage among 
young children and 
autism occurrence  
 
Methods: 
Retrospective 
analysis of MMR 
immunization 
coverage rates in 
children in California 
kindergartens and of 
autism caseloads 
among children who 
were enrolled in the 
California 
Department of 
Development 
Services  
• MMR 
immunization 
coverage rates as of 17 
months and 24 months 
and numbers of autism 
cases, grouped by year 
of birth  
No correlation was 
found; sustained 
increase in autism 
cases, while changes 
in immunization 
coverage where much 
smaller and of shorter 
duration  
• Immunization 
at 17 months used 
because this is just 
before the mean age 
when parents first 
notice 
developmental 
disorders  
• Immunization 
and autism records 
on the same 
individuals could not 
be linked  
 
Excluded 
- Autism and 
immunization 
records not 
linked to be 
able to 
determine a 
control group  
Appendix B (Continued) 
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2. DeFastano F, 
Bhasin TK, 
Thompson WW, 
et al. Age at first 
measles-mumps-
rubella 
vaccination in 
children with 
autism and 
school-matched 
control subjects: 
a population-
based study in 
metropolitan 
Atlanta. 
Pediatrics 
2004;113: 259-
266.  
Objective: To 
compare age at first 
MMR vaccination 
between children 
with autism and 
children who did not 
have autism 
 
Methods: Case-
control study using 
vaccination data 
abstracted from 
immunization forms 
for school entry  
• Odds Ratio 
determined by 
conditional logistic 
regression 
No significant 
associations for any 
age cutoff were found 
for specific case 
subgroups; More 
cases than control 
were vaccinated 
before 36 months 
(OR 1.49; OR 1.23 in 
the birth certificate 
cohort)  
• MMR vaccine 
increases the risk of 
autism, which 
usually develops 
before 24 months of 
age, if so then 
children vaccinated 
at younger ages 
would have a higher 
risk of developing 
autism  
• Compared 
cases and controls 
because they did not 
have an 
unvaccinated group 
and had incomplete 
information for 
determining the date 
of onset of autism  
Excluded 
-Study did not 
have a control 
group that was 
unvaccinated 
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3. DeWilde S, 
Carey I, Richards 
N, et al. Do 
children who 
become autistic 
consult more 
often after MMR 
vaccination? Br J 
Gen Pract. 
2001;51: 226-
227.  
Objective: To assess 
changes in parental 
concern as measured 
by a change in 
consultation behavior 
following MMR 
vaccination  
 
Methods: Case-
control study using the 
Doctor’s Independent 
Network database to 
count the number of 
consultations 
• Number of 
consultations before 
and after the MMR 
vaccination 
No significant 
differences in the 
numbers of 
consultations in the 6 
months before and 
two months after 
MMR between cases 
and control  
• Cases of 
autism could not be 
confirmed 
• Cases and 
controls both 
received the MMR 
vaccination  
Excluded 
-Study does 
not have an 
unvaccinated 
control group  
4. Farrington CP, 
Miller E, Taylor 
B. MMR and 
autism: further 
evidence against 
a causal 
association. 
Vaccine 2001;19: 
3632-3635.  
Objective: To test the 
hypothesis that MMR 
vaccination causes 
autism without pre-
specifying any fixed 
time interval after 
vaccination in which 
the risk of autism 
might be increased  
 
Methods: Self-
matched case series 
study  
• Relative 
incidence for autism 
diagnosis or 
regression following 
MMR vaccination 
In all instances the 
relative incidences 
did not differ 
significantly from 1, 
indicating no 
association between 
vaccination and 
autism in the 
subsequent risk 
periods  
• Study 
includes data on all 
MMR vaccines, 
including those 
given later than the 
recommended 
schedules  
Excluded 
-Second 
analysis of 
same study 
population; 
follow-up 
analysis of 
Taylor et al. 
(Lancet 1998) 
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5. Fombonne E, 
Zakarian R, 
Bennett A, et al. 
Pervasive 
developmental 
disorders in 
Montreal, 
Quebec, Canada: 
prevalence and 
links with 
immunizations. 
Pediatrics 
2006;118: e139-
e150.  
Objective: To estimate 
the pervasive 
developmental 
disorders in Montreal 
from 1987 to 1998 and 
to evaluate the 
relationship with 
changes in cumulative 
exposure to 
ethylmercury 
(thimerosal) and trends 
in MMR vaccination 
use rates   
 
Methods: Cohort study 
of children born 
between 1987 and 1996 
using surveys of 
vaccination rates and 
thimerosal exposure  
• Odds Ratio 
for thimerosal 
exposure 
• Odds Ratio 
for MMR 
vaccination use rates 
No significant effects 
of thimerosal 
exposure on the risk 
of developing a 
pervasive 
developmental 
disorder (OR 1.39 for 
exposure free vs. 
exposure); No 
association with 
MMR, as pervasive 
developmental 
disorders increased 
while MMR 
vaccination rates 
decreased (OR 1.10)  
• Children with 
a PPD diagnosis 
were identified by 
school officials and 
this diagnosis was 
not verified by direct 
assessment 
• Individual 
immunization data 
was not available  
Excluded 
-Study did not 
have an 
unvaccinated 
control group 
as individual 
immunization 
data was not 
available  
6. Geier DA, 
Geier MR. A 
comparative 
evaluation of the 
effects of MMR 
immunization 
and mercury 
doses from 
thimerosal-
Objective: To evaluate 
the effects of MMR 
immunization and 
mercury from 
thimerosal-containing 
vaccines on the 
prevalence of autism  
 
Methods: 
• Linear 
regression 
coefficients  
-Prevalence of 
autism in relation to 
average mercury 
doses 
-Number of doses of 
primary pediatric 
Close correlation 
between mercury 
doses from 
thimerosal-containing 
vaccines and 
prevalence of autism; 
Potential correlation 
between MMR 
vaccines and the 
• Examined 
cohorts of children 
and did not look at 
individuals therefore 
can only detect large 
universal effects  
• Evidence to 
support association 
with MMR vaccine 
Excluded 
-Study did not 
have an 
unvaccinated 
control group  
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containing 
childhood 
vaccines on the 
population 
prevalence of 
autism. Med Sci 
Monit. 
2004;10(3): 
P133-P139.  
Retrospective cohort 
study of the Biological 
Surveillance 
Summaries of the 
CDC, the US 
Department of 
Education dataset and 
the CDC’s yearly live 
birth estimates   
MMR vaccine to the 
prevalence of autism 
• Odds Ratios 
from average 
increased mercury 
exposure received 
from thimerosal-
containing vaccines   
prevalence of autism  is lacking (OR are 
not reported)  
7. Geier DA, 
Geier MR. 
Nuerodevelopme
ntal disorders 
following 
thimerosal-
containing 
childhood 
immunizations: a 
follow-up 
analysis. Int J 
Toxicol. 
2004;23(6): 369-
376.  
Objective: To 
determine if the 
previously observed 
effect between 
thimerosal-containing 
childhood vaccines and 
neurodevelopmental 
disorders are still 
present after children 
have had time to 
further mature 
 
Methods: Cohort study 
of children receiving 
thimerosal-containing 
vaccines to those not 
receiving thimerosal-
containing vaccines 
from 1997 to 2000  
• Odds ratio for 
development of 
neurodevelopmental 
disorders  
Significantly 
increased OR for 
developmental 
disorders for autism 
(OR 1.8), mental 
retardation (OR 2.6), 
speech disorder (OR 
2.1), personality 
disorder (OR 2.6) and 
thinking abnormality 
(OR 8.2)  
• Limitations of 
the Vaccine Adverse 
Events Reporting 
Dataset include: 
underreporting, 
erroneous reporting, 
frequent multiple 
exposures, multiple 
outcomes, and lack 
of precise 
denominators  
• Study of 
DTaP vaccine and 
not MMR  
Excluded 
-Study 
exposure does 
not include 
MMR 
vaccination  
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8. Goldman GS, 
Yazbak FE. An 
investigation of 
the association 
between MMR 
vaccination and 
autism in 
Denmark. 
Journal of 
American 
Physicians and 
Surgeons 
2004;9(3): 70-
75.  
Objective: To compare 
the prevalence of 
autism in the periods 
preceding an following 
the introduction of the 
MMR vaccine in 
Denmark  
 
Methods: Cohort study 
using data from 
nationwide 
computerized 
registration system in 
Denmark  
• Linear 
regression on the 
prevalence of autism 
by age cohorts  
• Relative Risk 
of  autism (adjusted 
for greater 
diagnostic 
awareness)  
RR of autism 
following 
introduction of MMR 
vaccine is 8.5 and 
adjusted risk is 4.7; 
suggests a temporal 
association between 
the introduction of 
the MMR vaccine 
and the rise in autism 
• The 20-24 
year old cohort 
potentially could 
have received the 
monovalent vaccine 
as toddlers and the 
MMR booster dose 
when it became 
available  
• Adjusted RR 
is highly sensitive to 
the increasing trend 
during 3 years, 1990 
to 1992  
Included  
9. Hilton S, Hunt 
K, Petticrew M. 
MMR: 
marginalized, 
misrepresented 
and rejected? 
Autism: a focus 
group study 
[abstract]. Arch 
Dis Child 2007; 
92: 322-327.  
Objective: To explore 
how the MMR vaccine 
controversy impacted 
the lives of parents 
caring for children with 
autism  
 
Methods: Qualitative 
focus group study 
conducted in the UK  
• Parent’s 
perception of the 
MMR vaccine and 
their response to the 
controversy 
surrounding the 
vaccine and autism 
Many parents felt the 
vaccine could be too 
potent for children 
who are susceptible 
to developing autism; 
Many felt guilty that 
they may have 
contributed to their 
child’s autism   
• Non-
experimental design 
(focus group study)  
Excluded 
-Study does 
not have an 
unvaccinated 
control group 
(non-
experimental 
design)  
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10. Honda H, 
Shimizu Y, 
Rutter M. No 
effect of MMR 
withdrawal on 
the incidence of 
autism: a total 
population study.  
J Child Psychol 
Psychiatry 
2005;46(6): 572-
579  
Objective: To compare 
autism frequency 
before and after the 
termination of the 
MMR vaccination 
program  
 
Methods: Analysis of 
annual trends in autism 
spectrum disorder 
incidence in Japan  
• MMR 
vaccination rates and 
the corresponding 
incidence of autism 
cases  
• Risk factor 
analysis using 
logistic regression  
The incidence of 
autism increased in 
birth cohorts both 
before and after 
MMR vaccinations 
were discontinued; 
statistically 
significant increase in 
autism incidence after 
the discontinuation of 
the MMR vaccination 
program  
• In Japan 
children only receive 
one dose of MMR as 
opposed to the initial 
vaccination and a 
booster shot as is the 
custom in most 
countries  
• Provides 
epidemiological data 
on the effect of the 
removal of the MMR 
vaccine 
(hypothesized 
offending agent)  
Included 
11. Hviid A, 
Stellfeld M, 
Wohlfahrt J, 
Melbye M. 
Association 
between 
thimerosal-
containing 
vaccine and 
autism. JAMA 
2003; 290(13): 
1763- 1766.  
Objective: To 
determine whether 
vaccination with a 
thimerosal-containing 
vaccine is associated 
with development of 
autism  
 
Methods: Cohort study 
of all children born in 
Denmark from 1990 to 
1996 comparing 
children vaccinated 
• RR for autism 
and other autistic-
spectrum disorders, 
including trend with 
dose of ethylmercury 
Risk of autism did 
not differ 
significantly between 
children vaccinated 
with thimerosal-
containing vaccines 
and those without 
(RR 0.85 for autism; 
RR 1.12 for autistic-
spectrum disorders)  
 
No evidence of a 
dose response (RR 
• Examined 
children vaccinated 
with a thimerosal-
containing 
formulation of the 
pertussis vaccine 
compared with 
pertussis vaccine 
without thimerosal  
Excluded 
-Study 
exposure does 
not include 
MMR 
vaccination 
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with a thimerosal-
containing vaccine and 
a thimerosal-free 
vaccine formulation  
0.98)  
 
12. Kaye JA, 
Melero-Montes 
M, Jick H. 
Mumps, measles, 
and rubella 
vaccine and the 
incidence of 
autism recorded 
by general 
practioners: a 
time trend 
analysis. BMJ 
2001;322: 460-
463.  
Objective: To estimate 
the changes in the risk 
of autism and assess 
the relation of autism to 
the MMR vaccine  
 
Methods: Time trend 
analysis of data from 
the UK general practice 
research database 
(GRPD)  
• Annual and 
age specific 
incidence for first 
recorded diagnosis 
of autism and 
coverage rates for 
the MMR vaccine 
Incidence of autism 
increased sevenfold 
in the birth cohorts, 
while the vaccine 
coverage rate 
remained above 95%; 
Suggests no 
association between 
MMR vaccine and 
autism incidence  
• Initially 
intended to do a 
case-control study, 
but only 3% of cases 
and controls were 
not vaccinated  
• Did not obtain 
and evaluate full 
clinical record 
information from 
general practioners 
to describe more 
fully the 
characteristics of 
children diagnosed 
with autism  
Excluded 
-Study does 
not contain an 
unvaccinated 
control group  
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13. Madsen KM, 
Vestergaard M. 
MMR 
vaccination and 
autism: What is 
the evidence for 
a causal 
association? 
Drug Safety 
2004;27(12): 
831-840.  
 Objective: To study 
the evidence on MMR 
vaccines and the 
occurrence of autism 
with particular focus on 
the epidemiological 
literature 
 
Methods: Literature 
review  
• Case series 
• Case-control 
studies 
• Ecological 
studies  
• Cross-
sectional studies 
• Cohort studies 
Review of the 
literature does not 
support a causal 
relationship between 
MMR vaccines and 
autism; No primates 
models exist and the 
biologic plausibility 
remains questionable 
• Literature 
review that identified 
10 epidemiological 
studies with none 
reporting a causal 
association  
Excluded 
-Study does 
not contain 
an 
unvaccinated 
control group 
14. Madsen KM, 
Hviid A, 
Vestergaard M, 
et al. A 
population-based 
study of measles, 
mumps, and 
rubella 
vaccination and 
autism. N Eng J 
Med. 
2002;347(19): 
1477-1482.  
Objective: To evaluate 
the hypothesized 
association of MMR 
vaccine and autism  
 
Methods: 
Retrospective cohort 
study of all children 
born in Denmark from 
January 1991 to 
December 1998  
• Relative risk 
of autistic disorder  
The RR of autistic 
disorder was 0.92 
and the RR of 
another autism-
spectrum disorder 
was 0.83; strong 
evidence against a 
causal association  
• Exposure data 
was collected 
prospectively, 
independent of 
parental recall and 
before the diagnosis of 
autism 
• Assumed that 
the data on MMR 
vaccination is 
complete because 
practioners in 
Denmark are 
reimbursed only after 
reporting immuniza-
tions to the National 
Board of Health  
Included  
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15. Makela A, 
Nuorti JP, 
Peltola H. 
Neurologic 
disorders after 
measles-mumps-
rubella 
vaccination. 
Pediatrics 
2002;110: 957-
963.  
Objective: To assess 
whether an association 
prevails between MMR 
vaccination and 
encephalitis, aseptic 
meningitis and autism 
 
Methods: 
Retrospective cohort 
study of individual 
MMR vaccination data 
from a hospital 
discharge register of 
children vaccinated 
between November 
1982 and June 1986  
• Total number 
of hospitalizations 
for autism after 
MMR vaccination 
during the study 
period 
• Number of 
events within 3 
month risk intervals 
post-vaccination 
compared with the 
number expected for 
encephalitis and 
aseptic meningitis  
Did not detect any 
clustering of 
hospitalizations for 
autism after 
vaccination; Did not 
identify any 
association between 
MMR vaccination 
and encephalitis, 
aseptic meningitis, 
and autism  
• Follow-up was 
extended to the end of 
the study for each 
child vaccinated 
because of the 
undefined latency of 
disease  
• Authors did not 
have access to 
outpatient records and 
not all autism cases are 
treated as inpatients  
• Exact incidence 
of autism could not be 
determined because 
autism develops subtly 
over long periods of 
time and some patients 
may be effected at 
birth but not 
symptomatic until later 
in life  
Excluded 
-Study did 
not have an 
unvaccinated 
control group 
16. Parker SK, 
Schwartz B, 
Todd J, 
Pickering LK. 
Thimerosal-
containing 
vaccines and 
Objective: To assess 
the quality of evidence 
assessing a potential 
association between 
thimerosal-containing 
vaccines and autism  
 
• 10 
epidemiological 
studies and 2 
pharmacokinetic 
studies of 
ethylmercury  
Studies do not 
demonstrate a link 
between thimerosal-
containing vaccines 
and autism, and the 
pharmacokinetics of 
ethylmercury make 
• Results of 
epidemiological 
studies have several 
inherent limitations 
such as: differences in 
study population, 
multiple potential 
Excluded 
-Study does 
not have an 
unvaccinated 
control group 
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autism spectrum 
disorder: a 
critical review of 
published 
original data. 
Pediatrics 
2004;114: 793-
804.  
Methods: Literature 
review of original 
published articles from 
1996 to 2004  
such an association 
less likely  
sources of bias, and 
the potential effects of 
confounding  
17. Patja A, 
Davidkin I, 
Kurki T, et al. 
Serious adverse 
events after 
measles-mumps-
rubella 
vaccination 
during a 
fourteen-year 
prospective 
follow-up. 
Pediatr Infect 
Dis J. 
2000;19(12): 
1127-1134.  
Objective: To 
distinguish events 
having a causal relation 
with MMR vaccination 
from those with only a 
temporal relation 
 
Methods: Prospective 
follow-up study using a 
passive surveillance 
system launched by the 
Finnish National Board 
of Health  
• Serious 
adverse events 
following MMR 
vaccination (no time 
frame was imposed) 
30 cases of 
anaphylaxis were 
reported and febrile 
seizures were the 
most commonly 
reported event; 
There were no cases 
of autism associated 
with MMR 
vaccination during 
the 14 year period 
• Lack of a 
control group due to a 
near fully vaccinated 
population 
• The 14 year 
follow-up allows for 
ample time to identify 
cases of autism in the 
3 million vaccine 
doses  
Excluded 
-Study does 
not have an 
unvaccinated 
control group 
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18. Richler J, 
Luyster R, Risi 
S, et al. Is there a 
‘regressive 
phenotype’ of 
autism spectrum 
disorder 
associated with 
the measles-
mumps-rubella 
vaccine? A 
CPEA study.  J 
Autism Dev Dis 
2006; 36(3): 
299-316.  
Objective: To assess 
whether a new 
phenotype of regressive 
autism is present and to 
assess the association 
with MMR vaccination 
 
Methods: A multi-site 
case-control study 
using data collected 
from 10 sites across the 
US as part of the 
Collaborative Program 
for Excellence in 
Autism (CPEA)  
• Analyses 
from the initial ADI-
R and algorithm 
scores from the most 
recent ADI-R and 
ADOS as well as 
standard scores from 
the Vineland 
Adaptive Behavior 
Scales and verbal 
and non-verbal IQ 
scores  
Findings of present 
study provides no 
evidence that 
regression in autism 
is associated with 
MMR vaccination; 
Much like children 
with autism in 
general, children 
with autism and 
regression are a 
heterogeneous group 
with varying 
trajectories of 
development  
• Children with 
autism and regression 
should have more 
social and 
communicative skills 
prior to loss but still 
show signs of atypical 
early development 
• Children with 
regressive autism 
should show different 
outcomes in terms of 
social and 
communicative skills 
• If regressive 
autism is associated 
with GI symptoms, 
then regressive autism 
patients should have 
more GI disorders/ 
symptoms than normal 
autism patients 
• Age at onset of 
autistic symptoms 
should more closely 
follow age at MMR 
vaccination  
• Limitation was 
Excluded 
-Study 
endpoints do 
not allow for 
the 
calculation of 
a RR or OR 
for the 
association of 
MMR and 
autism  
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that information about 
child’s early 
development was 
provided by 
retrospective parent 
report, which is open 
to bias  
19. Smeeth L, 
Hall AJ, 
Fombonne E, et 
al. A case-
control study of 
autism and 
mumps-measles-
rubella 
vaccination using 
the general 
practice research 
database: design 
and 
methodology.  
BMC Public 
Health 2001; 1:2.  
Objective: To 
determine if autistic 
children are more likely 
to have received MMR 
vaccination prior to 
disease onset and to 
examine whether there 
is any association 
between clinical onset 
of disease and the 
timing of MMR 
vaccination  
 
Methods: A matched 
case-control study 
using data derived from 
the UK General 
Practice Research 
Database  
• Conditional 
logistic regression to 
assess the 
association between 
MMR vaccination 
and autism (Odds 
ratio)  
• Case series 
analyses to estimate 
the relative 
incidence of autism 
in defined time 
intervals after 
vaccination  
No results reported  • Copies of all 
hospital summaries 
will be requested to 
validate the diagnosis 
of autism  
Excluded 
-Study does 
not allow for 
the 
calculation of 
an OR or RR 
for the 
association of 
MMR and 
autism  
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20. Smeeth L, 
Cook C, 
Fombonne E, et 
al. MMR 
vaccination and 
pervasive 
developmental 
disorders: a case-
control study.  
Lancet 2004;364: 
963-969.  
Methods and 
objectives described 
above 
Described above The OR for the 
association between 
MMR and pervasive 
developmental 
disorder was 0.86 
(0.68-1.09) 
suggesting no 
association between 
MMR vaccination 
and increased risk of 
pervasive 
developmental 
disorders  
• Case reports 
were obtained for 87% 
of patients to validate 
the diagnosis of a 
pervasive 
developmental 
disorder  
• Limitation was 
that when children 
joined a participating 
general practice after 
the date of MMR 
vaccination, their 
previous vaccination 
history was recorded 
retrospectively  
Included  
21. Takahashi H, 
Suzumura S, 
Shirakizawa F, et 
al. An 
epidemiological 
study of Japanese 
autism concerning 
routine childhood 
immunization 
history. Jpn J 
Infect Dis. 
2003;56: 114-117.  
Objective: To assess 
the causal association 
of autism with the 
MMR vaccine  
 
Methods: A case-
control study of 
adjusted logistic 
regression analysis on 
subjects growing up in 
the Tokyo area 
between 1988 and 
• Logistic 
regression analysis 
(Odds ratio)  
The OR for 
monovalent measles 
immunization (OR 
5.33), non-mumps 
immunization (OR 
8) and non-rubella 
immunization (OR 
8.57) with the 
development of 
autistic spectrum 
disorders; Suggests a 
decreased risk of 
• Only 21 cases 
were enrolled in the 
study  
• Results may be 
biased by the informed 
consent process, which 
may have discouraged 
caregivers from 
enrolling children with 
a poor or incomplete 
immunization history  
• Compared 
Excluded 
-Study did 
not have an 
unvaccinated 
control group 
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1992  autism with MMR 
vaccines compared 
with monovalent 
antigens  
MMR vaccine to 
monovalent antigens  
22. Taylor B. 
Vaccines and the 
changing 
epidemiology of 
autism. Child 
Care Health Dev 
2006;32(5): 511-
519.  
Objective: To review 
the available literature 
on the association 
between autism and 
MMR vaccination  
 
Methods: Literature 
review and 
interpretation  
• Interpretation 
of published studies 
on the association 
between autism and 
MMR vaccination  
The recorded 
prevalence of autism 
has increased 
considerably in 
recent years. The 
strong genetic 
component makes a 
post-natal cause 
unlikely  
• Diagnostic 
procedures for 
determining special 
educational disabilities 
such as autism are not 
standardized nor have 
they been uniform 
over time  
Excluded 
-Study did 
not have an 
unvaccinated 
control group 
23. Taylor B, 
Miller E, 
Farrington CP, et 
al. Autism and 
measles, mumps, 
and rubella 
vaccine: no 
epidemiological 
evidence for a 
causal 
association. 
Lancet 1999; 353: 
2026-29.  
Objective: To 
investigate whether 
MMR vaccine may be 
causally associated 
with autism 
 
Methods: 
Epidemiological study 
of children born with 
autism since 1979 in 
the UK using the case-
series method to 
investigate the 
clustering of onsets in 
the post vaccination 
period  
• Time trend 
analysis 
• Relative risk 
of temporal 
association of 
autism and MMR 
vaccination  
• Case series 
for temporal 
association  
Steady increase in 
cases by year of 
birth with no sudden 
step up or change in 
trend line; no 
temporal association 
between autism 
onset with one or 
two years of MMR 
vaccination (0.94, 
1.09)  
• Diagnosis of 
autism was confirmed 
based on medical 
records  
• Limitation was 
not that the diagnosis 
could not be verified 
in all cases and the 
ascertainment may 
have been incomplete  
• Clinical notes 
were of variable 
quality and many did 
not contain updated 
information  
Included  
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24. Taylor B, 
Miller E, Lingam 
R, et al. Measles, 
mumps, and 
rubella 
vaccination and 
bowel problems 
or developmental 
regression in 
children with 
autism: 
population study. 
BMJ 2002;324: 
393-396.  
Objective: To 
investigate whether 
MMR vaccination is 
associated with bowel 
problems and 
developmental 
regression in children 
with autism   
 
Methods: Population 
study with case note 
review to 
independently 
recorded vaccine data  
• Recorded 
bowel problems 
lasting at least three 
months, age of 
reported regression 
and relation to 
MMR vaccination 
• Single and 
multivariate logistic 
regression 
The proportion of 
children with 
developmental 
regression (OR 0.98) 
or bowel symptoms 
did not change 
significantly during 
the 20 years from 
1979; findings 
provide no support 
for an MMR 
associated “new 
variant” form of 
autism with 
developmental 
regression and 
bowel problems  
• The percentage 
of patients with 
regression (25%) is 
likely an 
overestimation  
• Limitation was 
that data were not 
recorded 
systematically and 
there was variability in 
the level of detail  
Included   
25. Thompson 
WW, Price C, 
Goodson B, et al. 
Early thimerosal 
exposure and 
neuropsychologic
al outcomes at 7 
to 10 years.  N 
Engl J Med. 2007; 
357(13): 1281-
1292.  
Objective: To assess 
the association 
between current 
neuropsychological 
performance and 
exposure to mercury 
during the prenatal 
period, postnatal 
period, and the first 7 
months of life  
 
Methods: Cohort 
• Neuropsychol
ogical outcomes 
associated with 
thimerosal 
(mercury) exposure  
• Measures of 
association 
measured with 
ordinary least-
squares regression 
and logistic 
regression  
Only a few 
significant 
associations with 
exposure to mercury 
from thimerosal 
were found; the 
detected associations 
were small and 
almost equally 
divided between 
positive and 
negative effects  
• Study did not 
assess autism-
spectrum disorders  
• Mercury 
exposure was 
determined based on 
published data and the 
data from the FDA on 
the vaccines that the 
children received, 
from HMO records, 
immunization records, 
Excluded 
-Study 
exposure did 
not include 
MMR 
vaccination  
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study of 1047 children 
between the ages of 7 
and 10 years 
administered 
standardized tests 
assessing 42 
neuropsychological 
outcomes  
and maternal interview 
• Limitations 
include a potential 
selection bias due to a 
majority of selected 
families declining to 
participate and the 
inability to control for 
interventions such as 
speech therapy that 
may have biased 
results toward the null  
26. Uchiyama T, 
Kurosawa M, 
Inaba Y. MMR 
vaccination and 
regression in 
autism spectrum 
disorders: 
negative results 
presented from 
Japan. J Autism 
Dev Disord 
2007;37: 210-217.  
Objective: To 
investigate whether 
the MMR vaccination 
is associated with 
“regressive autism”  
 
Methods: Case-
control comparison of 
children who received 
and did not receive the 
MMR vaccination and 
the change over time 
in the proportion of 
children who showed 
regressive symptoms 
across the pre-MMR, 
MMR and post-MMR 
• Odds ratio for 
the association 
between regression 
and MMR exposure 
The OR for those in 
the MMR group who 
received the vaccine 
was 0.744 (0.349-
1.517); The odds 
ratio for children 
who did not receive 
the vaccine across 
the three generations 
was 0.626 (0.323-
1.200); the rate of 
regression did not 
vary across the pre-
MMR, the MMR 
and the post-MMR 
cohorts  
• In Japan the 
MMR vaccine was 
only given between 
1985 and 1991 and 
thus allows for 
comparison of the 
before, during, and 
after effect of MMR 
vaccination  
• Assumed that 
information in the 
Maternal and Child 
Handbook was 
accurate as most of the 
information is entered 
by health professionals 
• Limitations: 
Included  
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time frames in Japan  study conducted in one 
private clinic, the 
sample size of subjects 
who received the 
MMR vaccine was 
small, and several 
issues concerning 
definition and 
measurement of 
regression 
(information was 
highly dependant on 
parental report using 
an instrument which 
asks limited questions 
on regression)  
27. Wakefield AJ, 
Murch SH, 
Linnell J, Casson 
DM, et al. Illeal-
lymphoid-nodular 
hyperplasia, non-
specific colitis, 
and pervasive 
developmental 
disorder in 
children. Lancet 
1998;351: 637-
641.  
Objective:  To 
investigate a series of 
children presenting 
with chronic 
enterocolitis and 
regressive 
developmental 
disorder following 
vaccination with the 
MMR vaccine  
 
Methods: 
Consecutive series 
• Temporal 
association between 
symptom onset and 
vaccination  
In 8 of the 12 
children the onset of 
behavioral problems 
was linked to MMR 
vaccination by the 
parent or child’s 
physician; Once 
child received the 
monovalent measles 
vaccine after which 
his development 
slowed  
• Potential 
selection bias in self-
referred group  
• Small sample 
size (12 children)  
• Lack of control 
group 
• Temporal 
association largely 
depends on parent 
recall and when they 
first notice signs of 
developmental 
Excluded 
-Study did 
not have an 
unvaccinated 
control group 
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analysis of 12 children 
with chronic 
enterocolitis and 
regressive 
developmental 
disorder  
regression  
28. Wilson K, 
Mills E, Ross C, 
et al. Association 
of autistic 
spectrum disorder 
and the measles, 
mumps, and 
rubella vaccine. 
Arch Pediatr 
Adoles Med. 
2003;157: 628-
634.  
 Objective: To 
systematically review 
the evidence for and 
against the existence 
of an association 
between autistic 
spectrum disorder and 
the MMR vaccine  
 
Methods: Systematic 
review of medical 
literature to identify 
all controlled 
epidemiological 
articles examining the 
association between 
autistic spectrum 
disorder and MMR 
vaccination  
• 12 
epidemiological 
studies assessing the 
association between 
autistic spectrum 
disorder and MMR 
vaccination  
The results of all of 
the studies showed 
no association 
between autistic 
spectrum disorders 
and the MMR 
vaccine  
• Studies 
included: case-series, 
cross-sectional studies, 
case-control studies, 
and retrospective 
cohort studies 
• Studies varied 
in how autistic 
spectrum disorder was 
diagnosed  
Excluded 
-Study did 
not have an 
unvaccinated 
control group 
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29. Woo EJ, Ball 
R, Bostrom A, et 
al. Vaccine risk 
perception 
among reporters 
of autism after 
vaccination: 
vaccine adverse 
event reporting 
system 1990-
2001. Am J 
Public Health 
2004; 94(6): 
990-995.  
Objective: To 
investigate vaccine risk 
perception among 
reporters of autism to 
the Vaccine Adverse 
Event Reporting 
System (VAERS)  
 
Methods: Structured 
interviews were 
conducted of 124 
patients who reported 
autism to VAERS 
between 1990 and 2001 
compared to published 
survey results of 
parents in the general 
population 
• Perceptions of 
parents of children 
with autism who 
believe that 
vaccinations may 
have been a cause  
Only 15% deemed 
immunizations 
extremely important 
for children’s health; 
two-thirds had 
withheld vaccines 
from their children  
• Passive 
surveillance systems 
such as VAERS are 
subject to many 
limitations including: 
underreporting, 
incomplete 
information, 
inadequate 
denominator data, and 
lack of an unbiased 
comparison group  
Excluded 
-Study did 
not allow for 
the 
calculation of 
an OR or RR 
for the 
association 
between 
autism and 
MMR  
 
